Chembio Diagnostics Awarded $3.2 Million Contract from the CDC for Development and Clinical Validation of Dual-Path Platform Syphilis Screen & Confirm Assay

Stock Information for Chembio Diagnostics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Chembio Diagnostics Inc.

Biosynex Completes Acquisition of Chembio Diagnostics, Inc.
Shareholder Alert: Ademi LLP investigates whether Chembio Diagnostics, Inc. has obtained a Fair Price in its transaction with Biosynex
Chembio Stockholders Urged to Tender Shares Before 6:00 P.M., New York City Time, on April 26, 2023
Biosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc.
Chembio Stockholders Reminded to Tender Shares Before 6:00 P.M., New York City Time, on April 12, 2023
Chembio's CEO Letter to Stockholders
Biosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc.
Chembio Stockholders Reminded to Tender Shares Before 6:00 PM New York City Time, on March 28, 2023

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.